Drug Profile
FP 101
Alternative Names: FP-101Latest Information Update: 10 Nov 2023
Price :
$50
*
At a glance
- Originator Fervent Pharmaceuticals
- Class Vascular disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Hot flashes; Menopausal syndrome
Most Recent Events
- 26 Oct 2023 Fervent Pharmaceuticals completes a phase-II trial in Menopausal syndrome (In adults, In the elderly) in USA (PO) (NCT05312567)
- 13 Jul 2022 Phase II development in Hot flashes (In adults, In the elderly) is ongoing in USA (PO) (NCT05312567)
- 28 Apr 2019 No recent reports of development identified for preclinical development in Menopausal-syndrome in USA (PO)